Key points are not available for this paper at this time.
In this post hoc analysis in people with type 2 diabetes, including those with chronic kidney disease, tirzepatide was associated with a clinically relevant decreased UACR versus comparators, suggesting a potential kidney-protective effect.
Apperloo et al. (2025) studied this question.